CLEVELAND, Aug. 31 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(Boston Stock Exchange:CFB), today announced that the company is scheduled to present at the Roth Capital Partners New York Growth Stock Conference to be held September 7-8.

Michael Fonstein, Ph.D., President and Chief Executive Officer at Cleveland BioLabs, will give a presentation on the company followed by a question and answer session on September 7, at 12:00 p.m. ET. The presentation will be broadcast live over the Internet. Interested parties may tune in to the live presentation by visiting the company's website at: or alternatively

Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is a small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has received approval to initiate Phase II trials with CBLC102 in hormone refractory prostate cancer.

The Company's other lead compound, CBLB502, is a modified protein of a microbe that protects cells from apoptosis. It has shown efficacy in protection against lethal doses of radiation in rodents and non-human primates and is on an accelerated approval pathway for the treatment of acute radiation syndrome, which results from exposure to high levels of radiation following a nuclear or radiological incident. Other applications for this technology include protection from cancer treatment side effects.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company with the goal to identify and develop new types of drugs for the protection of normal tissues from exposure to radiation and other stresses and for cancer treatment. Our development efforts are based on discoveries made in connection with the investigation of the cell-level process known as apoptosis. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors." We caution readers not to place undue reliance on these forward-looking statements. Although forward-looking statements help provide complete information about future prospects, readers should keep in mind that forward- looking statements are much less reliable than historical information.